California State Teachers Retirement System boosted its position in Seres Therapeutics Inc. (NASDAQ:MCRB) by 106.0% during the second quarter, Holdings Channel reports. The firm owned 37,380 shares of the company’s stock after buying an additional 19,233 shares during the period. California State Teachers Retirement System owned 0.09% of Seres Therapeutics worth $1,086,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of MCRB. Flagship Ventures Fund IV L.P. purchased a new position in Seres Therapeutics during the first quarter worth $374,060,000. BlackRock Fund Advisors increased its position in Seres Therapeutics by 8.2% in the first quarter. BlackRock Fund Advisors now owns 716,515 shares of the company’s stock worth $19,031,000 after buying an additional 54,438 shares during the period. Bridger Management LLC purchased a new position in Seres Therapeutics during the first quarter worth $18,890,000. Flagship Ventures Fund 2007 L.P. purchased a new position in Seres Therapeutics during the first quarter worth $15,917,000. Finally, BlackRock Group LTD increased its position in Seres Therapeutics by 0.8% in the first quarter. BlackRock Group LTD now owns 197,805 shares of the company’s stock worth $5,254,000 after buying an additional 1,505 shares during the period. 78.28% of the stock is currently owned by institutional investors and hedge funds.
Seres Therapeutics Inc. (NASDAQ:MCRB) traded down 2.84% during trading on Monday, hitting $13.02. The stock had a trading volume of 618,455 shares. The company’s market capitalization is $524.37 million. The stock’s 50-day moving average price is $11.23 and its 200-day moving average price is $24.02. Seres Therapeutics Inc. has a 1-year low of $8.05 and a 1-year high of $44.51.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Thursday, August 11th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.46) by $0.24. The firm earned $3 million during the quarter, compared to analysts’ expectations of $4.20 million. During the same quarter in the prior year, the business earned ($1.45) earnings per share. The company’s revenue was up NaN% on a year-over-year basis. Analysts expect that Seres Therapeutics Inc. will post ($2.33) earnings per share for the current year.
MCRB has been the topic of a number of research reports. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Friday, July 29th. HC Wainwright began coverage on Seres Therapeutics in a research note on Friday, July 29th. They issued a “buy” rating and a $50.00 price objective for the company. Canaccord Genuity reissued a “buy” rating and issued a $20.00 price objective on shares of Seres Therapeutics in a research note on Monday, August 1st. Zacks Investment Research downgraded Seres Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 19th. Finally, FBR & Co lowered their price objective on Seres Therapeutics from $43.00 to $23.00 and set an “outperform” rating for the company in a research note on Friday, August 12th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $31.57.
In related news, CFO Eric D. Shaff sold 4,533 shares of the firm’s stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $29.54, for a total value of $133,904.82. Following the sale, the chief financial officer now directly owns 4,533 shares of the company’s stock, valued at $133,904.82. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John G. Aunins sold 9,390 shares of the firm’s stock in a transaction dated Monday, August 29th. The stock was sold at an average price of $10.87, for a total value of $102,069.30. Following the completion of the sale, the insider now directly owns 192,125 shares in the company, valued at $2,088,398.75. The disclosure for this sale can be found here. 41.90% of the stock is owned by corporate insiders.
Seres Therapeutics Company Profile
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics Inc. (NASDAQ:MCRB).
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.